ArticleIranian journal of basic medical sciences2025
Anemoside B4 mitigates endoplasmic reticulum stress-induced apoptosis post cerebral ischemia/reperfusion injury in rats.
Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anemoside B4 (AB4) exhibits neuroprotective effects on cerebral ischemia/reperfusion injury (CIRI), and endoplasmic reticulum stress (ERS) plays a crucial role in the process of CIRI. Nevertheless, it remains unknown whether AB4 acts on CIRI via ERS. This study is designed to determine whether AB4 mitigates CIRI by suppressing ERS-induced neuronal apoptosis. Materials and Methods: One hundred thirty-five male SD rats (260-290 g) were randomly assigned to five groups, with 20 rats in each group: 1. Sham. 2. Middle Cerebral Artery Occlusion (MCAO/R). 3. AB4-L: Prior to MCAO, rats were subjected to continuous intraperitoneal injection of 1.25 mg/kg of AB4. 4. AB4-M: Rats were administered a continuous intraperitoneal injection of 2.5 mg/kg of AB4 prior to undergoing MCAO. 5. AB4-H: Rats were continuously intraperitoneally injected with 5 mg/kg of AB4 before MCAO. Additionally, another thirty-five rats were employed for the time point. Results: TTC staining results demonstrated that AB4 significantly reduced cerebral infarct volume. Histopathological analysis of brain tissues revealed that AB4 mitigated neuronal damage. In the MCAO model, GRP78 expression progressively increased with reperfusion time and peaked at 24 hr. AB4 treatment decreased mRNA levels of key ERS markers, including GRP78, ATF6, IRE1α, and PERK. Additionally, AB4 reduced protein levels of GRP78, p-PERK, PERK, ATF6, and p-IRE1α, further indicating its role in attenuating ERS. TUNEL results demonstrated that AB4 significantly reduced neuronal apoptosis. Conclusion: AB4 may serve as a potential therapeutic agent for CIRI, potentially exerting neuroprotective effects through inhibiting ERS-mediated apoptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.